Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes
Authors
Keywords
-
Journal
Frontiers in Cell and Developmental Biology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-08-13
DOI
10.3389/fcell.2021.727531
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A novel tricyclic BTK inhibitor suppresses B cell responses and osteoclastic bone erosion in rheumatoid arthritis
- (2021) Yu-ting Liu et al. ACTA PHARMACOLOGICA SINICA
- Observations on the use of Bruton’s tyrosine kinase inhibitors in SAR-CoV-2 and cancer
- (2021) Brooke Benner et al. Journal of Hematology & Oncology
- Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia
- (2021) Paolo Ghia et al. LEUKEMIA & LYMPHOMA
- The European Medicines Agency Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia
- (2021) Julio Delgado et al. ONCOLOGIST
- Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function
- (2021) Tony J. Zheng et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Risk of bleeding complications and atrial fibrillation associated with ibrutinib treatment: A systematic review and meta-analysis
- (2021) Luca Pellegrini et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Ibrutinib interferes with innate immunity in chronic lymphocytic leukemia patients during COVID-19 infection
- (2021) Stefania Fiorcari et al. HAEMATOLOGICA
- Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia
- (2021) Isabelle G. Solman et al. LEUKEMIA RESEARCH
- BTK Inhibition Reverses MDSC-Mediated Immunosuppression and Enhances Response to Anti-PDL1 Therapy in Neuroblastoma
- (2021) Mehreen Ishfaq et al. Cancers
- Targeting the NLRP3 Inflammasome via BTK
- (2021) Alexander N. R. Weber Frontiers in Cell and Developmental Biology
- Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects
- (2021) H. Yesid Estupiñán et al. Frontiers in Cell and Developmental Biology
- Feasibility and efficacy of CD19-targeted CAR-T cells with concurrent ibrutinib for CLL after ibrutinib failure
- (2020) Jordan Gauthier et al. BLOOD
- Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells
- (2020) Sanjay Varikuti et al. BRITISH JOURNAL OF CANCER
- Ibrutinib-associated Arthralgias/Myalgias in Patients with Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes
- (2020) Joanna M. Rhodes et al. Clinical Lymphoma Myeloma & Leukemia
- Low dose Btk inhibitors selectively block platelet activation by CLEC-2
- (2020) Phillip L.R. Nicolson et al. HAEMATOLOGICA
- Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma
- (2020) Ajai Chari et al. HEMATOLOGICAL ONCOLOGY
- Bruton’s tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells
- (2020) Ahmed Nadeem et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Effective upfront treatment with low-dose ibrutinib for a patient with B cell prolymphocytic leukemia
- (2020) Satoko Oka et al. INVESTIGATIONAL NEW DRUGS
- Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib
- (2020) Jim S. Qin et al. JOURNAL OF IMMUNOTHERAPY
- Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia
- (2020) Jennifer A. Woyach et al. Cancer Discovery
- Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer
- (2020) Michael Overman et al. Journal for ImmunoTherapy of Cancer
- Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition
- (2020) Albert Liclican et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients
- (2020) Steven P. Treon et al. BLOOD
- The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma
- (2020) Nathan H. Fowler et al. BRITISH JOURNAL OF HAEMATOLOGY
- Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape
- (2020) Lorenzo Iovino et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Bruton tyrosine kinase deficiency augments NLRP3 inflammasome activation and causes IL-1β–mediated colitis
- (2020) Liming Mao et al. JOURNAL OF CLINICAL INVESTIGATION
- ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2020) Paolo Ghia et al. JOURNAL OF CLINICAL ONCOLOGY
- Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
- (2020) Jeff P Sharman et al. LANCET
- The effect of ibrutinib on neutrophil and γδ T cell functions
- (2020) Denise Risnik et al. LEUKEMIA & LYMPHOMA
- Ibrutinib for the treatment of chronic graft‐vs‐host disease in pediatric hematopoietic stem cell transplant patients: A single‐center experience
- (2020) Ashley Teusink‐Cross et al. PEDIATRIC TRANSPLANTATION
- Management of Ibrutinib Toxicities: a Practical Guide
- (2020) Masa Lasica et al. Current Hematologic Malignancy Reports
- Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data
- (2020) Krista Isaac et al. Cancer Management and Research
- The role of Bruton’s tyrosine kinase inhibitors in the management of mantle cell lymphoma
- (2020) Kirollos S Hanna et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Dermatological Toxicities of Bruton’s Tyrosine Kinase Inhibitors
- (2020) Vincent Sibaud et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience
- (2020) Katharine L. Lewis et al. BRITISH JOURNAL OF HAEMATOLOGY
- Inhibition of Bruton's tyrosine kinase regulates macrophage NF‐κB and NLRP3 inflammasome activation in metabolic inflammation
- (2020) Gareth S.D. Purvis et al. BRITISH JOURNAL OF PHARMACOLOGY
- A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer
- (2020) Tian Zhang et al. CANCER
- Cutaneous adverse‐events in patients treated with Ibrutinib
- (2020) Alessandro Pileri et al. Dermatologic Therapy
- Therapeutic treatment with Ibrutinib attenuates imiquimod-induced psoriasis-like inflammation in mice through downregulation of oxidative and inflammatory mediators in neutrophils and dendritic cells
- (2020) Naif O. Al-Harbi et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma
- (2020) David A. Bond et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Infectious Complications of Tyrosine Kinase Inhibitors in Hematological Malignancies
- (2020) Andrew Kin et al. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
- Ibrutinib for improved chimeric antigen receptor T‐cell production for chronic lymphocytic leukemia patients
- (2020) Fuli Fan et al. INTERNATIONAL JOURNAL OF CANCER
- Ibrutinib in Gynecological Malignancies and Breast Cancer: A Systematic Review
- (2020) Julian Matthias Metzler et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Bruton’s tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis
- (2020) Melanie C. Dispenza et al. JOURNAL OF CLINICAL INVESTIGATION
- Ibrutinib suppresses intracellular mycobacterium tuberculosis growth by inducing macrophage autophagy
- (2020) Yunlong Hu et al. JOURNAL OF INFECTION
- BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID‐19 therapy
- (2020) Michael C. McGee et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib
- (2020) Elena A. Dmitrieva et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
- (2020) Lydia Scarfò et al. LEUKEMIA
- Ibrutinib Restores Immune Cell Numbers and Function in First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia
- (2020) Isabelle G. Solman et al. LEUKEMIA RESEARCH
- Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
- (2020) Mark Roschewski et al. Science Immunology
- Current and Emerging Treatments for Waldenström Macroglobulinemia
- (2020) Christopher N. Grimont et al. ACTA HAEMATOLOGICA
- Ibrutinib-Mediated Atrial Fibrillation Due to Inhibition of CSK
- (2020) Ling Xiao et al. CIRCULATION
- Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: a Systematic Review and Network Meta-analysis
- (2020) Matthew S. Davids et al. CLINICAL THERAPEUTICS
- Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia
- (2020) Steven P. Treon et al. JOURNAL OF CLINICAL ONCOLOGY
- Ibrutinib Suppresses Early Megakaryopoiesis but Enhances Proplatelet Formation
- (2020) Jiansong Huang et al. THROMBOSIS AND HAEMOSTASIS
- Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib‐based combination therapy: A real‐world experience of off‐label ibrutinib use
- (2020) Feili Chen et al. Cancer Medicine
- BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia
- (2020) Stefania Fiorcari et al. Frontiers in Immunology
- Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2
- (2020) Verena Barbarino et al. Cancers
- Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy
- (2020) Joanne E. Davis et al. Blood Advances
- Incorporating acalabrutinib, a selective next‐generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies
- (2020) Alexey V. Danilov et al. BRITISH JOURNAL OF HAEMATOLOGY
- Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma
- (2020) Solomon A. Graf et al. Clinical Lymphoma Myeloma & Leukemia
- A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre‐ibrutinib era
- (2020) Vilhjálmur Steingrímsson et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Bruton’s tyrosine kinase inhibition attenuates oxidative stress in systemic immune cells and renal compartment during sepsis-induced acute kidney injury in mice
- (2020) Ahmed Nadeem et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Relevance of the Bruton Tyrosine Kinase (BTK) as a target for COVID-19 therapy
- (2020) Miran Rada et al. MOLECULAR CANCER RESEARCH
- Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation
- (2020) Brendan P. Hodkinson et al. Translational Oncology
- Managing toxicities of Bruton tyrosine kinase inhibitors
- (2020) Andrew Lipsky et al. Hematology-American Society of Hematology Education Program
- Chemotherapy-free frontline therapy for CLL: is it worth it?
- (2020) Joanna M. Rhodes et al. Hematology-American Society of Hematology Education Program
- Management of Waldenström macroglobulinemia in 2020
- (2020) Jorge J. Castillo et al. Hematology-American Society of Hematology Education Program
- Does Ibrutinib impact outcomes of viral infection by SARS-CoV-2 in mantle cell lymphoma patients?
- (2020) Tamim Alsuliman et al. Current Research in Translational Medicine
- Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse
- (2020) Sarah Cadot et al. Biomarker Research
- Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis
- (2020) Ariela Noy et al. Blood Advances
- Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia
- (2019) Alexander P. de Porto et al. MOLECULAR MEDICINE
- Monocyte-to-macrophage switch reversibly impaired by Ibrutinib
- (2019) Isacco Ferrarini et al. Oncotarget
- The Tec kinase ITK is essential for ILC2 survival and epithelial integrity in the intestine
- (2019) Hyoung-Soo Cho et al. Nature Communications
- Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib
- (2019) Viola Denzinger et al. THROMBOSIS AND HAEMOSTASIS
- Differences and similarities in ibrutinib and acalabrutinib effects on platelet functions
- (2019) Jennifer Series et al. HAEMATOLOGICA
- Acalabrutinib for Mantle Cell Lymphoma
- (2019) Thomas E Witzig et al. BLOOD
- Chronic lymphocytic leukaemia: the role of T cells in a B cell disease
- (2019) Stephen Man et al. BRITISH JOURNAL OF HAEMATOLOGY
- Genetic Deficiency and Biochemical Inhibition of ITK Affect Human Th17, Treg, and Innate Lymphoid Cells
- (2019) Ahmet Eken et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Inhibiting Bruton’s Tyrosine Kinase in CLL and Other B-Cell Malignancies
- (2019) Fabienne Lucas et al. Targeted Oncology
- Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs?
- (2019) Kristina Busygina et al. THROMBOSIS AND HAEMOSTASIS
- Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study
- (2019) Edmund K. Waller et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Antigen presentation by dendritic cells for B cell activation
- (2019) William R Heath et al. CURRENT OPINION IN IMMUNOLOGY
- Studying interactions between dendritic cells and T cells in vivo
- (2019) Aleksey Chudnovskiy et al. CURRENT OPINION IN IMMUNOLOGY
- Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus
- (2019) Damien Blez et al. HAEMATOLOGICA
- Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK cell effector function in patients with mantle cell lymphoma
- (2019) Thijs W.H. Flinsenberg et al. HAEMATOLOGICA
- B lymphocytes inactivation by Ibrutinib limits endometriosis progression in mice
- (2019) L G C Riccio et al. HUMAN REPRODUCTION
- Structural and diffusion weighted MRI demonstrates responses to ibrutinib in a mouse model of follicular helper (Tfh) T-cell lymphoma
- (2019) Rebecca L. Allchin et al. PLoS One
- T-cell expression of Bruton’s tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia
- (2019) Simo Xia et al. Cellular & Molecular Immunology
- Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes
- (2019) Tom Hofland et al. JOURNAL OF IMMUNOLOGY
- Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators
- (2019) João Conniot et al. Nature Nanotechnology
- Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice
- (2019) Caroline E. O'Riordan et al. Frontiers in Immunology
- Evidence for interaction of the NLRP3 inflammasome and Bruton’s tyrosine kinase in tumor-associated macrophages: implications for myeloid cell production of interleukin-1beta
- (2019) Brooke Benner et al. OncoImmunology
- Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections
- (2019) Rossana Maffei et al. BLOOD REVIEWS
- Risk of Infection Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-analysis of Randomized Controlled Trials
- (2019) Somedeb Ball et al. Clinical Lymphoma Myeloma & Leukemia
- Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma
- (2019) Claire Telford et al. CLINICAL THERAPEUTICS
- An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma
- (2019) Fortunato Morabito et al. EXPERT OPINION ON PHARMACOTHERAPY
- Riesgo de infección asociado a nuevas terapias para el tratamiento de los síndromes linfoproliferativos
- (2019) Ibai Los-Arcos et al. MEDICINA CLINICA
- Ibrutinib in CLL/SLL: From bench to bedside (Review)
- (2019) Fuming Zi et al. ONCOLOGY REPORTS
- Inhibition of Bruton’s tyrosine kinase and IL-2 inducible T-cell kinase suppresses both neutrophilic and eosinophilic airway inflammation in a cockroach allergen extract-induced mixed granulocytic mouse model of asthma using preventative and therapeutic strategy
- (2019) Ahmed Nadeem et al. PHARMACOLOGICAL RESEARCH
- Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results
- (2019) John C. Byrd et al. BLOOD
- Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL
- (2019) Maissa Mhibik et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Cutaneous Eruptions from Ibrutinib Resembling EGFR Inhibitor-Induced Dermatologic Adverse Events
- (2019) Sean Singer et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment
- (2019) Alessandro Prezzo et al. LEUKEMIA RESEARCH
- Long-Term Ibrutinib Therapy Reverses CD8+ T Cell Exhaustion in B Cell Chronic Lymphocytic Leukaemia
- (2019) Helen M. Parry et al. Frontiers in Immunology
- Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study
- (2019) Roger G Owen et al. Lancet Haematology
- Self-limiting Ibrutinib-Induced Neutrophilic Panniculitis
- (2018) Jacob Stewart et al. AMERICAN JOURNAL OF DERMATOPATHOLOGY
- Inhibiting Bruton’s tyrosine kinase rescues mice from lethal influenza-induced acute lung injury
- (2018) Jon M. Florence et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- Bruton's tyrosine kinase regulates TLR7/8-induced TNF transcription via nuclear factor-κB recruitment
- (2018) Theresa H. Page et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Ibrutinib blocks Btk-dependent NF-ĸB and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis
- (2018) Amelia Bercusson et al. BLOOD
- Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque–triggered thrombus formation in humans
- (2018) Kristina Busygina et al. BLOOD
- The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity
- (2018) Jasper Rip et al. CRITICAL REVIEWS IN IMMUNOLOGY
- The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC)
- (2018) Jun Chen et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation to GPVI
- (2018) Phillip L.R. Nicolson et al. HAEMATOLOGICA
- Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy
- (2018) Melanie C. Dispenza et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
- (2018) Michael Wang et al. LANCET
- Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia
- (2018) Christopher Pleyer et al. LEUKEMIA & LYMPHOMA
- Role of Bruton’s tyrosine kinase in B cells and malignancies
- (2018) Simar Pal Singh et al. Molecular Cancer
- Myeloid-derived suppressor cells coming of age
- (2018) Filippo Veglia et al. NATURE IMMUNOLOGY
- The B cell receptor signaling pathway in mantle cell lymphoma
- (2018) Maria I. Merolle et al. Oncotarget
- Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors
- (2018) Floyd Hassenrück et al. Biomed Research International
- Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation to GPVI
- (2018) Phillip L.R. Nicolson et al. HAEMATOLOGICA
- Improving CLL Vγ9Vδ2-T cell fitness for cellular therapy by ex vivo activation and ibrutinib
- (2018) Iris de Weerdt et al. BLOOD
- The potent ITK/BTK inhibitor Ibrutinib is effective for the treatment of experimental visceral leishmaniasis caused by Leishmania donovani
- (2018) Sanjay Varikuti et al. JOURNAL OF INFECTIOUS DISEASES
- Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia
- (2018) Gayane Manukyan et al. LEUKEMIA RESEARCH
- Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma
- (2018) Sami Mamand et al. Scientific Reports
- Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies
- (2018) Karl R. VanDerMeid et al. Cancer Immunology Research
- Acalabrutinib and its use in treatment of chronic lymphocytic leukemia
- (2018) Yasir Khan et al. Future Oncology
- A novel Bruton's tyrosine kinase inhibitor acalabrutinib suppresses osteoclast differentiation and P. gingivalis lipopolysaccharide-induced alveolar bone resorption
- (2018) Nitin Kumar Pokhrel et al. JOURNAL OF PERIODONTOLOGY
- Regulation of NLRP3 Inflammasome by Phosphorylation
- (2018) Nan Song et al. Frontiers in Immunology
- Potential applications of Bruton’s tyrosine kinase inhibitors for the prevention of allergic reactions
- (2017) Melanie C. Dispenza et al. Expert Review of Clinical Immunology
- The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activation
- (2017) Nicole Stadler et al. HAEMATOLOGICA
- The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies
- (2017) Josée Golay et al. HAEMATOLOGICA
- Ibrutinib, a Bruton’s tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity
- (2017) Jennifer A. Regan et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Human NACHT, LRR, and PYD domain–containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase
- (2017) Xiao Liu et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Ibrutinib treatment improves T cell number and function in CLL patients
- (2017) Meixiao Long et al. JOURNAL OF CLINICAL INVESTIGATION
- Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia
- (2017) Qingsong Yin et al. JOURNAL OF IMMUNOLOGY
- Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
- (2017) Tjeerd Barf et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number
- (2017) Monika Podhorecka et al. Oncotarget
- The Bruton’s tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages
- (2017) Lingyan Ping et al. Oncotarget
- The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activation
- (2017) Nicole Stadler et al. HAEMATOLOGICA
- The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies
- (2017) Josée Golay et al. HAEMATOLOGICA
- Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity
- (2017) Alexander N. R. Weber et al. Frontiers in Immunology
- The lack of BTK does not impair monocytes and polymorphonuclear cells functions in X-linked agammaglobulinemia under treatment with intravenous immunoglobulin replacement
- (2017) Filomena Monica Cavaliere et al. PLoS One
- Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT
- (2016) C. E. Ryan et al. BLOOD
- Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
- (2016) Joseph A. Fraietta et al. BLOOD
- Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment
- (2016) Andrew Stiff et al. CANCER RESEARCH
- The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma
- (2016) M. Ruella et al. CLINICAL CANCER RESEARCH
- Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells
- (2016) Viralkumar Patel et al. CLINICAL CANCER RESEARCH
- Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
- (2016) Jingjing Wu et al. Journal of Hematology & Oncology
- Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms
- (2016) M Ruella et al. LEUKEMIA
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia
- (2016) Stefania Fiorcari et al. Oncotarget
- Ibrutinib as an antitumor immunomodulator in patients with refractory chronic lymphocytic leukemia
- (2016) Carolina Cubillos-Zapata et al. OncoImmunology
- A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells
- (2016) Gayathri Natarajan et al. OncoImmunology
- Innate Immune Recognition of Cancer
- (2015) Seng-Ryong Woo et al. Annual Review of Immunology
- Abstract 2596: ACP-196: a novel covalent Bruton's tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients
- (2015) Todd Covey et al. CANCER RESEARCH
- Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib - Findings from an Investigator-Initiated Phase II Study
- (2015) C. U. Niemann et al. CLINICAL CANCER RESEARCH
- Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages
- (2015) M. Borge et al. HAEMATOLOGICA
- Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib
- (2015) A. H. Lipsky et al. HAEMATOLOGICA
- Distinct Pathways Regulate Syk Protein Activation Downstream of Immune Tyrosine Activation Motif (ITAM) and hemITAM Receptors in Platelets
- (2015) Bhanu Kanth Manne et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function
- (2015) Li Ren et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib
- (2015) Rossana Maffei et al. Journal of Hematology & Oncology
- Role of Bruton’s tyrosine kinase inhibitors in HIV-1-infected cells
- (2015) Irene Guendel et al. JOURNAL OF NEUROVIROLOGY
- Macrophages eat cancer cells using their own calreticulin as a guide: Roles of TLR and Btk
- (2015) Mingye Feng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targets for Ibrutinib Beyond B Cell Malignancies
- (2015) A. Berglöf et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Inhibition of the kinase ITK in a mouse model of asthma reduces cell death and fails to inhibit the inflammatory response
- (2015) Yonglian Sun et al. Science Signaling
- Bruton’s tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury
- (2015) Minako Ito et al. Nature Communications
- Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients
- (2015) F Boissard et al. Blood Cancer Journal
- Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer
- (2015) A. J. Gunderson et al. Cancer Discovery
- Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia
- (2015) Genevra Pillinger et al. Scientific Reports
- Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages
- (2015) M. Borge et al. HAEMATOLOGICA
- Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib
- (2015) A. H. Lipsky et al. HAEMATOLOGICA
- Inhibition of the kinase ITK in a mouse model of asthma reduces cell death and fails to inhibit the inflammatory response
- (2015) Yonglian Sun et al. Science Signaling
- Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells
- (2015) Stuart A Rushworth et al. Lancet Haematology
- Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells
- (2015) Gayathri Natarajan et al. OncoImmunology
- Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML
- (2015) Lyubov Zaitseva et al. Oncotarget
- Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity
- (2014) H. E. Kohrt et al. BLOOD
- Tyrosine phosphorylation in Toll-like receptor signaling
- (2014) Saurabh Chattopadhyay et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy
- (2014) F. D. Roit et al. HAEMATOLOGICA
- Bruton tyrosine kinase mediates TLR9-dependent human dendritic cell activation
- (2014) Vassilios Lougaris et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Itk-mediated integration of T cell receptor and cytokine signaling regulates the balance between Th17 and regulatory T cells
- (2014) Julio Gomez-Rodriguez et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Dual Functions of Bruton's Tyrosine Kinase and Tec Kinase during Fc Receptor-Induced Signaling and Phagocytosis
- (2014) J. Jongstra-Bilen et al. JOURNAL OF IMMUNOLOGY
- The Phosphoinositide 3-Kinase-Dependent Activation of Btk Is Required for Optimal Eicosanoid Production and Generation of Reactive Oxygen Species in Antigen-Stimulated Mast Cells
- (2014) H. S. Kuehn et al. JOURNAL OF IMMUNOLOGY
- B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies
- (2014) K Bojarczuk et al. LEUKEMIA
- Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies
- (2014) Minh Ngoc Duong et al. mAbs
- Btk Regulates Macrophage Polarization in Response to Lipopolysaccharide
- (2014) Joan Ní Gabhann et al. PLoS One
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
- (2013) J. A. Dubovsky et al. BLOOD
- Circulating microenvironment of CLL: Are nurse-like cells related to tumor-associated macrophages?
- (2013) Agata A. Filip et al. BLOOD CELLS MOLECULES AND DISEASES
- The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss
- (2013) Masahiro Shinohara et al. BONE
- Bruton's Tyrosine Kinase (BTK) and Vav1 Contribute to Dectin1-Dependent Phagocytosis of Candida albicans in Macrophages
- (2013) Karin Strijbis et al. PLoS Pathogens
- The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
- (2012) M. F. M. de Rooij et al. BLOOD
- Sensitization to Cockroach Allergen: Immune Regulation and Genetic Determinants
- (2012) Peisong Gao Clinical & Developmental Immunology
- Tyrosine Kinase Btk Is Required for NK Cell Activation
- (2012) Yan Bao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils
- (2012) Fumiko Honda et al. NATURE IMMUNOLOGY
- Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response
- (2012) K.-G. Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Btk is a positive regulator in the TREM-1/DAP12 signaling pathway
- (2011) T. Ormsby et al. BLOOD
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
- (2011) S. E. M. Herman et al. BLOOD
- The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
- (2011) S. Ponader et al. BLOOD
- Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor
- (2011) Donald MacGlashan et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Toll-like receptor 4–, 7–, and 8–activated myeloid cells from patients with X-linked agammaglobulinemia produce enhanced inflammatory cytokines
- (2011) Thomas U. Marron et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk
- (2011) Xingguang Liu et al. NATURE IMMUNOLOGY
- The Tec Family Tyrosine Kinase Btk Regulates RANKL-induced Osteoclast Maturation
- (2008) Seoung Hoon Lee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started